Effect of rebagit on gastric mucosa in patients with nsaid gastropathy

Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/2510

Full metadata record

DC Field	Value	Language
dc.contributor.author	Musaeva L. J., Akbarova D.S., Pulatova N.I., Saifieva N.H.	-
dc.date.accessioned	2022-10-07T05:41:06Z	-
dc.date.available	2022-10-07T05:41:06Z	-
dc.date.issued	2022	-
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/2510	-
dc.description.abstract	The study involved 72 patients aged 20-65 years. Patients of the first group -35 patients received antisecretory therapy: pantoprazole 40 mg x 1 time daily during 14 days. Patients of the second group -37 people, against the background of pantoprazole 40 mg x once a day for 14 days received rebagit 100 mg 3 times a day. The criteria for selection to both groups were the presence of erosive changes of gastric mucosa and fresh ulcers on endoscopic examination	en_US
dc.language.iso	en	en_US
dc.publisher	Toshkent	en_US
dc.subject	Effect of rebagit on gastric mucosa, patients with nsaid gastropathy	en_US
dc.title	Effect of rebagit on gastric mucosa in patients with nsaid gastropathy	en_US
dc.type	Thesis	en_US
Appears in Collections:	Thesis, Articles

Files in This Item:

File	Description	Size	Format
1.pdf	Effect of rebagit on gastric mucosa in patients with nsaid gastropathy	199.62 kB	Adobe PDF	View/Open

DSpace JSPUI